Clinical trial
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
NCT06554301 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 20, 2024
- Completion date
- December 31, 2026
- Enrollment
- 72 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.